See the DrugPatentWatch profile for sarclisa

Sarclisa (isatuximab-irfc), a CD38 monoclonal antibody, is a treatment option for certain types of cancer, including multiple myeloma. When comparing Sarclisa to other CD38 antibodies, it is important to consider its mechanism of action, efficacy, and safety profile.

Sarclisa works by binding to CD38, a transmembrane glycoprotein expressed on the surface of hematopoietic cells, and inducing antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP). This results in the destruction of malignant cells.

In a phase 3 clinical trial, Sarclisa in combination with pomalidomide and dexamethasone showed a statistically significant improvement in progression-free survival (PFS) compared to pomalidomide and dexamethasone alone in patients with relapsed/refractory multiple myeloma [1].

Daratumumab (Darzalex) is another CD38 antibody that has been approved for the treatment of multiple myeloma. In a phase 3 clinical trial, daratumumab in combination with lenalidomide and dexamethasone significantly improved PFS compared to lenalidomide and dexamethasone alone in patients with newly diagnosed multiple myeloma [2].

When comparing Sarclisa and daratumumab, it is important to note that Sarclisa has shown efficacy in patients who have relapsed or are refractory to at least two prior therapies, while daratumumab has shown efficacy in both newly diagnosed and relapsed/refractory multiple myeloma.

In terms of safety, both Sarclisa and daratumumab have similar adverse events, including infusion reactions, neutropenia, and upper respiratory tract infections. However, the incidence and severity of these adverse events may vary between the two drugs [1][2].

In summary, Sarclisa is a CD38 antibody that has shown efficacy in patients with relapsed/refractory multiple myeloma, while daratumumab has shown efficacy in both newly diagnosed and relapsed/refractory multiple myeloma. Both drugs have similar safety profiles, but the incidence and severity of adverse events may vary.

Sources:
[1] Sarclisa (isatuximab-irfc) injection, for intravenous use. Prescribing information. San Diego, CA: Sanofi-Aventis U.S. LLC; 2021.
[2] Darzalex (daratumumab) injection, for intravenous use. Prescribing information. South San Francisco, CA: Genmab US, Inc.; 2021.
[3] CD38 monoclonal antibodies. DrugPatentWatch.com. <https://www.drugpatentwatch.com/drug/cd38-monoclonal-antibodies>. Accessed February 14, 2023.